| Schedule of worldwide net revenues |
The following table details AbbVie’s worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | | | | | | | | | | | | | | | | (in millions) | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | | | Immunology | | | | | | | | | | | | | | | Skyrizi | United States | $ | 4,767 | | | $ | 3,843 | | | $ | 8,542 | | | $ | 6,762 | | | | | | | | | International | 738 | | | 580 | | | 1,446 | | | 1,086 | | | | | | | | | Total | $ | 5,505 | | | $ | 4,423 | | | $ | 9,988 | | | $ | 7,848 | | | | | | | | | Rinvoq | United States | $ | 1,765 | | | $ | 1,452 | | | $ | 3,170 | | | $ | 2,672 | | | | | | | | | International | 760 | | | 576 | | | 1,474 | | | 1,074 | | | | | | | | | Total | $ | 2,525 | | | $ | 2,028 | | | $ | 4,644 | | | $ | 3,746 | | | | | | | | | Humira | United States | $ | 425 | | | $ | 802 | | | $ | 782 | | | $ | 1,546 | | | | | | | | | International | 331 | | | 378 | | | 662 | | | 755 | | | | | | | | | Total | $ | 756 | | | $ | 1,180 | | | $ | 1,444 | | | $ | 2,301 | | | | | | | | | Neuroscience | | | | | | | | | | | | | | | Vraylar | United States | $ | 1,068 | | | $ | 898 | | | $ | 1,970 | | | $ | 1,661 | | | | | | | | | International | 3 | | | 2 | | | 6 | | | 4 | | | | | | | | | Total | $ | 1,071 | | | $ | 900 | | | $ | 1,976 | | | $ | 1,665 | | | | | | | | | Botox Therapeutic | United States | $ | 864 | | | $ | 775 | | | $ | 1,706 | | | $ | 1,498 | | | | | | | | | International | 178 | | | 153 | | | 345 | | | 296 | | | | | | | | | Total | $ | 1,042 | | | $ | 928 | | | $ | 2,051 | | | $ | 1,794 | | | | | | | | | Ubrelvy | United States | $ | 379 | | | $ | 330 | | | $ | 709 | | | $ | 563 | | | | | | | | | International | 13 | | | 8 | | | 22 | | | 15 | | | | | | | | | Total | $ | 392 | | | $ | 338 | | | $ | 731 | | | $ | 578 | | | | | | | | | Qulipta | United States | $ | 289 | | | $ | 237 | | | $ | 539 | | | $ | 409 | | | | | | | | | International | 61 | | | 30 | | | 107 | | | 51 | | | | | | | | | Total | $ | 350 | | | $ | 267 | | | $ | 646 | | | $ | 460 | | | | | | | | | Vyalev | United States | $ | 128 | | | $ | 22 | | | $ | 217 | | | $ | 28 | | | | | | | | | International | 128 | | | 76 | | | 240 | | | 133 | | | | | | | | | Total | $ | 256 | | | $ | 98 | | | $ | 457 | | | $ | 161 | | | | | | | | | Other Neuroscience | United States | $ | 43 | | | $ | 71 | | | $ | 89 | | | $ | 146 | | | | | | | | | International | 74 | | | 81 | | | 153 | | | 161 | | | | | | | | | Total | $ | 117 | | | $ | 152 | | | $ | 242 | | | $ | 307 | | | | | | | | | Oncology | | | | | | | | | | | | | | | Venclexta | United States | $ | 369 | | | $ | 321 | | | $ | 710 | | | $ | 633 | | | | | | | | | International | 402 | | | 370 | | | 831 | | | 723 | | | | | | | | | Total | $ | 771 | | | $ | 691 | | | $ | 1,541 | | | $ | 1,356 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | | | | | | | | | | | | | | | | (in millions) | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | | | Imbruvica | United States | $ | 337 | | | $ | 543 | | | $ | 669 | | | $ | 1,072 | | | | | | | | | Collaboration revenues | 195 | | | 211 | | | 419 | | | 420 | | | | | | | | | Total | $ | 532 | | | $ | 754 | | | $ | 1,088 | | | $ | 1,492 | | | | | | | | | Elahere | United States | $ | 161 | | | $ | 138 | | | $ | 321 | | | $ | 303 | | | | | | | | | International | 50 | | | 21 | | | 88 | | | 35 | | | | | | | | | Total | $ | 211 | | | $ | 159 | | | $ | 409 | | | $ | 338 | | | | | | | | | Epkinly | Collaboration revenues | $ | 64 | | | $ | 49 | | | $ | 115 | | | $ | 85 | | | | | | | | | International | 39 | | | 21 | | | 71 | | | 36 | | | | | | | | | Total | $ | 103 | | | $ | 70 | | | $ | 186 | | | $ | 121 | | | | | | | | | Other Oncology | United States | $ | 33 | | | $ | 2 | | | $ | 57 | | | $ | 2 | | | | | | | | | Aesthetics | | | | | | | | | | | | | | | Botox Cosmetic | United States | $ | 400 | | | $ | 410 | | | $ | 771 | | | $ | 705 | | | | | | | | | International | 328 | | | 282 | | | 625 | | | 543 | | | | | | | | | Total | $ | 728 | | | $ | 692 | | | $ | 1,396 | | | $ | 1,248 | | | | | | | | | Juvederm Collection | United States | $ | 103 | | | $ | 105 | | | $ | 188 | | | $ | 180 | | | | | | | | | International | 142 | | | 155 | | | 289 | | | 311 | | | | | | | | | Total | $ | 245 | | | $ | 260 | | | $ | 477 | | | $ | 491 | | | | | | | | | Other Aesthetics | United States | $ | 258 | | | $ | 282 | | | $ | 506 | | | $ | 552 | | | | | | | | | International | 51 | | | 45 | | | 89 | | | 90 | | | | | | | | | Total | $ | 309 | | | $ | 327 | | | $ | 595 | | | $ | 642 | | | | | | | | | Other Key Products | | | | | | | | | | | | | | | Mavyret | United States | $ | 133 | | | $ | 184 | | | $ | 316 | | | $ | 326 | | | | | | | | | International | 162 | | | 191 | | | 330 | | | 355 | | | | | | | | | Total | $ | 295 | | | $ | 375 | | | $ | 646 | | | $ | 681 | | | | | | | | | Creon | United States | $ | 345 | | | $ | 404 | | | $ | 706 | | | $ | 759 | | | | | | | | Linzess | United States | $ | 283 | | | $ | 247 | | | $ | 555 | | | $ | 386 | | | | | | | | | International | 12 | | | 11 | | | 23 | | | 20 | | | | | | | | | Total | $ | 295 | | | $ | 258 | | | $ | 578 | | | $ | 406 | | | | | | | | | All other | | $ | 1,109 | | | $ | 1,117 | | | $ | 2,134 | | | $ | 2,370 | | | | | | | | | Total net revenues | $ | 16,990 | | | $ | 15,423 | | | $ | 31,992 | | | $ | 28,766 | | | | | | | |
|